Back to news

November 30, 2018 | International,

Reinventing Drug Discovery and Development for Military Needs

Flying at 50,000 feet, diving deep in the ocean, or hiking for miles with gear through extreme climates, military service members face conditions that place unique burdens on their individual physiology. The potential exists to develop pharmacological interventions to help service members complete their toughest missions more safely and efficiently, and then recover more quickly and without adverse effects, but those interventions must work on complex physiological systems in the human body. They will not be realized under the prevailing system of drug discovery and development with its focus on engaging single molecular targets. DARPA created the Panacea program to pursue the means of rapidly discovering, designing, and validating new, multi-target drugs that work with the body's complexity to better support the physiological resilience and recovery of military service members.

The premise of Panacea is that the physiological systems of the human body work in complex and highly integrated ways. Drugs exert effects on our bodies by physically interacting with and changing the functional state of biomolecules that govern the functions of cells and tissues. Most drugs target proteins, which are the principle cellular workhorses. Ideally, drugs would target multiple proteins simultaneously to exert precise, network-level effects.

One major problem facing the drug development community is that the functional proteome — the complete collection of proteins and their roles in signaling networks — is largely dark to science. Despite being able to identify many of the proteins within a cell, researchers do not have a firm grasp on everything those proteins do and how they interact to affect physiology.

Due to this sparsity of structural and functional knowledge, the state of the art in drug development — what Panacea seeks to transform — is to engage only a very small fraction of known protein targets to achieve an effect. In fact, today's approach to drug design singles out individual proteins in certain cells. That hyper-specificity is an attempt to minimize the risk of side effects and speed time to market, but it also yields a thin stream of drugs, many of which have similar mechanisms and relatively muted effectiveness compared to what might be achieved using a multi-target, systems-based approach.

“The current roster of drugs approved by the U.S. Food and Drug Administration only targets about 549 proteins, yet the body can produce more than six million different protein variants,” said Tristan McClure-Begley, the Panacea program manager. “The opportunity space for pharmacological intervention is vast and effectively untapped, but to access it we need new technology for understanding and targeting the human functional proteome.”

Panacea will address the lack of functional knowledge about the proteome. DARPA's call to the research community is to consider complex physiological conditions relevant to military service members — for instance, metabolic stress during extreme endurance missions or pain and inflammation after injury; investigate the molecular mechanisms underlying those conditions; identify multiple, key molecular targets involved; and develop novel medicinal chemistry approaches to synthesize interventions that modulate those targets. DARPA believes that multi-target drugs will deliver safer and more efficacious solutions to military requirements for readiness and recovery over state-of-the-art interventions.

“Many of the most successful drugs produced in the past were found rather than made, and we knew what they did long before we knew how they did it,” McClure-Begley said. “To deliver improved interventions, we need to get to a place where we can investigate all of the potential proteins at play for a given condition and then prioritize sets of protein targets and signaling networks to effectively modulate physiological systems, regardless of what prior knowledge exists about those targets.”

The Panacea program aims to generate initial proof of concept for this new direction in drug discovery and development. Research will primarily involve animal models, human cell derived organoids, and high-throughput cell culture models. However, to support eventual transition to humans, DARPA will work with federal agencies to develop a regulatory pathway for future medical use. By the end of the five-year program, DARPA will require teams to submit novel drug candidates to the U.S. Food and Drug Administration for review as an Investigational New Drug or for Compassionate Use.

DARPA will hold a Proposers Day on December 14, 2018, in Arlington, Virginia, to provide more information about Panacea and answer questions from potential proposers. For details of the event, including registration requirements, visit https://go.usa.gov/xP6hD.

A forthcoming Broad Agency Announcement will fully describe the program structure and objectives.

https://www.darpa.mil/news-events/2018-11-28

On the same subject

  • DARPA Seeks Secure Microchip Supply Chain

    June 1, 2020 | International, C4ISR

    DARPA Seeks Secure Microchip Supply Chain

    "Once a chip is designed, adding security after the fact or making changes to address newly discovered threats is nearly impossible," explains a DARPA spokesperson. By THERESA HITCHENSon May 29, 2020 at 2:46 PM WASHINGTON: DARPA has launched a four-year project to find ways to design security features into microchips as they are being made to help ensure the future supply chain. While the name of the project is daunting — Automatic Implementation of Secure Silicon (AISS) — and the technical requirements are a serious challenge, the concept is pretty simple. “AISS aims to automate the process of incorporating security into chip designs, making it easier and potentially more cost effective for any organization with even a small design team (start-ups, mid-size companies, etc.) to build security measures into their designs,” a DARPA spokesperson told Breaking D today. “Overall, with AISS DARPA aims to bring greater automation to the chip design process to profoundly decrease the burden of including security measures,” the spokesperson said. The two winning teams, according to a May 27 DARPA press release, are: The two AISS research teams are: Synopsys, Arm, Boeing, Florida Institute for Cybersecurity Research at the University of Florida, Texas A&M University, UltraSoC, and the University of California, San Diego Northrop Grumman, IBM, University of Arkansas, and University of Florida “Research and development on the $75 million program was commenced two weeks ago and incremental capabilities are expected to roll out to the chip design community over the next four years,” the spokesperson said in an email. “Our hope is that many of the capabilities will start appearing as features in commercial design automation software before the program completion.” Digital integrated circuits are the engines that drive modern computers, and everyday digital devices such as smart phones. They are critical to the evolution of the Internet of Things (IoT). As such, they increasingly have become a key target of hacking by US adversaries and cyber criminals alike, DARPA explains. “Threats to IC chips are well known, and despite various measures designed to mitigate them, hardware developers have largely been slow to implement security solutions due to limited expertise, high cost and complexity,” the DARPA release says. “Further, when unsecure circuits are used in critical systems, the lack of embedded countermeasures exposes them to exploitation.” Indeed, the Department of Commerce on May 15 took another swipe at Chinese telecoms behemoth Huawei and tightened its earlier efforts to block it from exporting its semiconductors and products to the US and allies. The Trump administration alleges that Huawei's hardware and software, in particular that related to 5G wireless technology, are full of deliberate security holes in order to enable Chinese government spying. The ruling by Commerce's Bureau of Industry and Security, which will take effect in September, seeks to prevent companies around the world from using American-made software and machinery develop chips for Huawei or its subsidiary firms. The problem for device-makers, particularly in the IoT world where the market is largely for commercial products (think smart refrigerators), is that fixing potential security holes often isn't seen as worth the time, effort and most importantly, money. “The inclusion of security also often requires certain trade-offs with the typical design objectives, such as size, performance, and power dissipation,” the DARPA spokesperson said. “For example, something like a sprinkler isn't likely to require the highest level of security protections. Investing in security mechanisms that take up a lot of space on the underlying chip, or significantly impact chip performance likely doesn't make sense based on the sprinkler's expected use and application.” And yet, that future IoT sprinkler also will be other IoT devices and computer networks in operation by an individual, a company or a facility, such as a weapons depot. Even more unfortunately, the spokesperson explained, “modern chip design methods are unforgiving – once a chip is designed, adding security after the fact or making changes to address newly discovered threats is nearly impossible.” Thus, the AISS program is aimed at spurring research into two areas that can address four types of microchip vulnerability, the release says: “side channel attacks, hardware Trojans, reverse engineering, and supply chain attacks, such as counterfeiting, recycling, re-marking, cloning, and over-production.” The first area of research will be focusing on “development of a ‘security engine' that combines the latest academic research and commercial technology into an upgradable platform that can be used to defend chips against attacks, and provide an infrastructure to manage these hardened chips as they progress through their lifecycle,” DARPA said. The second area, led by software specialists Synopsys, “involves integrating the security engine technology developed in the first research area into system-on-chip (SOC) platforms in a highly automated way,” the DARPA release said. The Synopsys team also will be working on how to integrate new security designs and manufacturing tools with currently available off-the-shelf products. Nicholas Paraskevopoulous, sector VP for emerging capabilities development at Northrop Grumman, said in a May 27 press release that the firm's “design tools will enable the development of secure and trusted integrated circuits with reduced costs.” Northrop Grumman is involved in the first AISS research area. Synopsis could not be reached for comment by press time. https://breakingdefense.com/2020/05/darpa-seeks-secure-microchip-supply-chain/

  • Airbus and Dassault Systèmes Embark on Strategic Partnership to Create the European Aerospace Industry of Tomorrow

    February 6, 2019 | International, Aerospace

    Airbus and Dassault Systèmes Embark on Strategic Partnership to Create the European Aerospace Industry of Tomorrow

    Airbus will deploy Dassault Systèmes' 3DEXPERIENCE platform to take major step forward in its digital transformation Airbus makes digital design, manufacturing and services a reality across all divisions and product lines Airbus and Dassault Systèmes (Paris:DSY) have signed a five-year Memorandum of Agreement (MOA) to cooperate on the implementation of collaborative 3D design, engineering, manufacturing, simulation and intelligence applications. This will enable Airbus to take a major step forward in its digital transformation and lay the foundation for a new European industrial ecosystem in aviation. Under the MOA, Airbus will deploy Dassault Systèmes' 3DEXPERIENCE platform, which delivers digital continuity, from design to operations, in a single data model for a unified user experience, making digital design, manufacturing and services (DDMS) a company-wide reality for all Airbus divisions and product lines. DDMS paves the way for breakthroughs in new product design, operational performance, support and maintenance, customer satisfaction and new business models, as it represents a move from sequential to parallel development processes. Instead of first focusing on product performance, Airbus will be able to co-design and develop the next generation of aircraft with the manufacturing facilities that will produce them, reducing costs and time to market. “We are not just talking about digitalisation or a 3D experience, we are rethinking the way aircraft are designed and operated, streamlining and speeding up our processes with customer satisfaction in mind,” said Guillaume Faury, President Airbus Commercial Aircraft. “DDMS is a catalyst for change and with it we are building a new model for the European aerospace industry with state of the art technology. Our target is a robust production setup that offers a reduction in product development lead time.” “Nothing exemplifies the intersection of technology, science and art more than aviation. When we reflect on how the industry has evolved to where it is today, it's a blend of technical prowess, digital precision and inspiration,” said Bernard Charlès, Vice Chairman and CEO, Dassault Systèmes. “The Aerospace industry has a proven track record of fast transformation, faster than in most industries. It delivers high quality innovation and new services for operations in highly complex and regulated environments. The 3DEXPERIENCE platform will accelerate the digital transformation of Airbus. Airbus can capture insights and expertise from across its ecosystem to deliver new experiences that only the digital world makes possible.” Share on Twitter: @Airbus @Dassault3DS embark on strategic partnership to create the European aerospace industry of tomorrow #digitaltransformation #smartmanufacturing #factoryofthefuture #3DEXPERIENCE * * * About Airbus Airbus is a global leader in aeronautics, space and related services. In 2017 it generated revenues of € 59 billion restated for IFRS 15 and employed a workforce of around 129,000. Airbus offers the most comprehensive range of passenger airliners from 100 to more than 600 seats. Airbus is also a European leader providing tanker, combat, transport and mission aircraft, as well as one of the world's leading space companies. In helicopters, Airbus provides the most efficient civil and military rotorcraft solutions worldwide. About Dassault Systèmes Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes' collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 250,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com. 3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries. This and other press releases and high resolution photos are available on: AirbusNewsroom https://www.businesswire.com/news/home/20190205006036/en/

  • Lithuania boosts defense budget to buy Switchblade drones

    September 29, 2022 | International, Aerospace

    Lithuania boosts defense budget to buy Switchblade drones

    In response to Russia's invasion of its neighbor Ukraine, Lithuania has decided to expand its military budget.

All news